| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| DOI:10.1002/etc.5620140607 | IVR | 0.002 mg/kg | 0.002 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations |
| PMID:10220852 | IVR | 0.00625 mg/kg/day | 0.00625 mg/kg/day | Increased LH levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.00625 mg/kg/day | 0.00625 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.00625 mg/kg/day | 0.00625 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| PMID:10919282 | IVR | 0.001 mg/kg | 0.001 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects lipid metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.00055 mg/kg | 0.00055 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.0003 mg/kg | 0.0003 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| PMID:12642156 | IVTH | 0.01 - 20 mg/L | 10 mg/L | Affects androgen signaling | Reproductive endocrine-mediated perturbations |
| IVTH | 0.01 - 20 mg/L | 0.1 - 20 mg/L | Decreased Dihydroxytestosterone (DHT) levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.01 - 20 mg/L | 0.1 - 20 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:16291562 | IVR | 0.000049 mg/kg/day | 0.000049 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| PMID:16396990 | IVTH | 0.00001 M | 0.00001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 M | 0.00001 M | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:18093177 | IVR | 100 mg/kg | 100 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Affects spatial learning | Neurological endocrine-mediated perturbations | |
| PMID:20574914 | IVTH | 0.00000000001 - 0.000004 M | 0.00000004 - 0.000004 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000000001 - 0.000004 M | 0.000004 M | Increase in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.00000000001 - 0.000004 M | 0.000004 M | Increased aldosterone levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00000000001 - 0.000004 M | 0.0000004 - 0.000004 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:24754389 | IVTH | 0.0000141 M | 0.0000141 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000141 M | 0.0000141 M | Increase in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.0000141 M | 0.0000141 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000004 M | 0.000004 M | Increase in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.000004 M | 0.000004 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000004 M | 0.000004 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:29175438 | IVR | 0.02 mg/kg | 0.02 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Decrease in Growth Hormone (GH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Reduced insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Reduced insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Decrease in Growth Hormone (GH) levels | Metabolic endocrine-mediated perturbations | |
| PMID:30312631 | IVR | 20000 mg/kg | 20000 mg/kg | Increased triglycerides level | Metabolic endocrine-mediated perturbations |
| IVR | 20000 mg/kg | 20000 mg/kg | Affects lipid metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 20000 mg/kg | 20000 mg/kg | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 20000 mg/kg | 20000 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 20000 mg/kg | 20000 mg/kg | Beta cell dysfunction | Metabolic endocrine-mediated perturbations | |
| IVR | 20000 mg/kg | 20000 mg/kg | Affects fatty acid metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:7672011 | IVR | 0.007 - 0.18 mg/kg | 0.007 - 0.18 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| PMID:9176554 | IVR | 0.1 mg/kg | 0.1 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Thymus atrophy | Immunological endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Thymus atrophy | Immunological endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | - | No significant effects observed | - |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.